Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study

Publication date: Available online 10 October 2019Source: Clinics and Research in Hepatology and GastroenterologyAuthor(s): Anne-Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet, Dominique Béchade, Isabelle Trouilloud, Nelson Lourenco, Vincent Hautefeuille, Christophe Locher, Nicolas Williet, Jérôme Desrame, Pascal Artru, Emilie Soularue, Bertrand Le Roy, Julien TaiebSummaryBackgroundA combination of nab-paclitaxel plus gemcitabine (N + G) has recently become a standard first-line treatment in patients with metastatic pancreatic adenocarcinoma (MPA), but there are currently no published data concerning second-line treatment after N + G. The aim of this study was to evaluate the survival outcomes and tolerability of three usual fluoropyrimidine-based regimens FOLFOX, FOLFIRI and FOLFIRINOX after N + G failure in MPA patients.MethodsPatients receiving N + G as first-line regimen were prospectively identified in 11 French centers between January 2014 and January 2017. After disease progression or unacceptable toxicity, patients eligible for second-line therapy were enrolled in the study. The primary endpoint was overall survival following the second-line regimen. Secondary endpoints were objective response, progression-free survival and safety.ResultsOut of 137 patients treated with N + G as first-line regimen, 61 (44.5%) received second-line chemotherapy, including FOLFOX (39.4%), FOLFIRI (34.4%) or ...
Source: Clinics and Research in Hepatology and Gastroenterology - Category: Gastroenterology Source Type: research

Related Links:

Conditions:   Pancreatic Adenocarcinoma;   Pancreatic Cancer Intervention:   Biological: Autologous DC vaccine Sponsors:   Baylor College of Medicine;   Cancer Cures for Kids Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Sanford NN, Aguilera TA, Folkert MR, Ahn C, Mahal BA, Zeh H, Beg MS, Mansour J, Sher DJ Abstract BACKGROUND: Adjuvant therapy for resected pancreatic adenocarcinoma was given a category 1 NCCN recommendation in 2000, yet many patients do not receive chemotherapy after definitive surgery. Whether sociodemographic disparities exist for receipt of adjuvant chemotherapy is poorly understood. METHODS: The National Cancer Database was used to identify patients diagnosed with nonmetastatic pancreatic adenocarcinoma who underwent definitive surgery from 2004 through 2015. Multivariable logistic regression defi...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
-Chuan Hung Both gemcitabine and fluoropyrimidine are recommended backbones in the first-line treatment of pancreatic ductal adenocarcinoma (PDAC). To compare the efficacy and safety of these two therapeutic backbones, and to investigate the optimal therapies, we conducted a network meta-analysis. By retrospective analysis of randomized controlled trials (RCT), the most preferred therapeutic regimen may be predicted. The eligible RCTs of the gemcitabine-based therapies and fluoropyrimidine-based therapies were searched up to 31 August 2019. In a frequentist network meta-analysis, treatments were compared and ranked acc...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
CONCLUSIONS: Pelareorep and pembrolizumab added to chemotherapy did not add significant toxicity and showed encouraging efficacy. Further evaluation of pelareorep and anti-PD-1 therapy is ongoing in follow-up studies. This research highlights the potential utility of several pre-treatment and on-treatment biomarkers for pelareorep therapy warranting further investigation. PMID: 31694832 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionRates of surgical resection after upfront chemotherapy are relatively low, and the proportion of patients who eventually undergo resection varies considerably between hospitals. The use of surgery after upfront chemotherapy in resectable pancreatic cancer should be considered as an internal quality-of-cancer-care measure.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
Conclusions Ascites-derived xenograft models represent a valuable experimental system for testing the efficacy of currently available therapeutic compounds on chemotherapy-resistant PDAC cells and for elucidation of the mechanisms underlying chemotherapy resistance.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
This study aimed to explore the prognostic significance of the resection margin (R) status of pancreatic ductal adenocarcinoma (PDAC) patients receiving neoadjuvant therapy (NAT) or adjuvant chemotherapy (AC).MethodsWe retrospectively reviewed 427 consecutive patients, and the overall survival (OS) and disease-free survival (DFS) were analyzed based on the R status by a propensity score analysis (PSA).ResultsThe R0 ratio of the NAT (+) group was significantly higher than that of the NAT ( −) group (97.2% vs. 69.6%,P 
Source: Surgery Today - Category: Surgery Source Type: research
Lukas Cerveny Evidence on equilibrative nucleoside transporter 1 (ENT1) and microRNA-21 (miR‑21) is not yet sufficiently convincing to consider them as prognostic biomarkers for patients with pancreatic ductal adenocarcinoma (PDAC). Here, we investigated the prognostic value of ENT1/ENT1, miR-21, and neurogenic locus homolog protein 3 gene (NOTCH3) in a well-defined cohort of resected patients treated with adjuvant gemcitabine chemotherapy (n = 69). Using a combination of gene expression quantification in microdissected tissue, immunohistochemistry, and univariate/multivariate statistical analyses we did not confirm ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 18 October 2019Source: Advances in Biological RegulationAuthor(s): Shaw M. Akula, Saverio Candido, Stephen L. Abrams, Linda S. Steelman, Kvin Lertpiriyapong, Lucio Cocco, Giulia Ramazzotti, Stefano Ratti, Matilde Y. Follo, Alberto M. Martelli, Ramiro M. Murata, Pedro L. Rosalen, Bruno Bueno-Silva, Severino Matias de Alencar, Marco Falasca, Giuseppe Montalto, Melchiorre Cervello, Monica Notarbartolo, Agnieszka Gizak, Dariusz RakusAbstractImproving the effects of chemotherapy and reducing the side effects are important goals in cancer research. Various approaches have been examined to enhan...
Source: Advances in Biological Regulation - Category: Biology Source Type: research
Conditions:   Pancreatic Cancer;   Pancreatic Adenocarcinoma Interventions:   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Drug: FOLFIRINOX Sponsor:   Indiana University Withdrawn
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | France Health | Gastroenterology | Pancreas | Pancreatic Cancer | Study | Toxicology